

IMCB Invited Speaker



Speaker : Dr. Teh Bin Tean
*Director and Principal Investigator, Laboratory of Cancer Epigenome,
National Cancer Centre Singapore*

Date : 19 November 2013, Tuesday

Time : 11:00AM - 12:00PM

Venue : IMCB Seminar Room 3-46, Level 3, Proteos, Biopolis

Host : Prof. Wanjin Hong

Seminar :

Asian Cancer Genomics - Novel Diagnostic and Therapeutic Targets

We focus on genomic profiling of cancer prevalent in Asian countries with the goal to use genomic data to elucidate the underlying molecular biology of these cancers. Studies on two cancer types will be presented: 1) NKT cell lymphoma that is 5 times more common in Asia than in the West, 2) Cholangiocarcinoma (bile duct cancer) that is endemic in northeast of Thailand and 3) Upper urinary tracturothelial cancer in Taiwan. A combination of different factors, including diet, social habits, ethnicity, carcinogens and pathogens (e.g., viruses, parasites) have been attributed to the difference in their prevalence. I will present our high-throughput genomic profiling efforts including whole exome sequencing in these cancers, their underlying biology and their clinical implications.

About the Speaker :

Professor Bin Tean Teh obtained his M.D. from the University of Queensland, Australia and his Ph.D. from the Karolinska Institute, Sweden. Following postdoctoral works in multiple endocrine neoplasia 1 at Karolinska Institute, Prof. Teh joined the Van Andel Research Institute (VARI) in 2000 as a Senior Scientific Investigator heading the Laboratory of Cancer Genetics. In 2007, Prof. Teh was appointed the founding Director of the National Cancer Centre Singapore (NCCS)-VARI laboratory, which serves as a bridge between translational research and clinical medicine. In 2010, he received the STaR award and relocated to Singapore and is currently a full professor. His laboratory focuses on genomic studies of cancers common among Asian populations, using tools such as high-throughput genomic platforms and correlation studies with clinico-pathological information. In the last three years, his group, in collaboration with others, has made significant advances in bile duct cancer, T-cell lymphoma, and urological cancer. His laboratory is also focusing on downstream works including transgenic animal modeling and synthetic lethal screening on chromatin enzymes in cancer. Prof. Teh has published extensively over 300 publications and also sits on various editorial boards for numerous biomedical journals.